Slaoui apologizes “unreservedly” after allegations of sexual harassment force biotechnology to disperse

No turning, no denial. Moncef Slaoui, Ph.D. Med., Has issued an open apology over allegations of sexual harassment that led to GlaxoSmithKline breaking up on Wednesday. But the biofarm world is currently not in a state of forgiveness.

“I would like to apologize unreservedly to the employee in question and I am deeply sorry for any trouble,” Slaoui said in a statement Wednesday.

The former CEO of GSK Vaccine and head of Operation Warp Speed ​​said he would “make an effort to redeem himself” with those affected, but for now will retire by stepping down from his current positions in the industry to focus on the family.

The apology came after GSK ousted him from the presidency of Galvani-controlled Galvani Bioelectronics for allegations of harassment and inappropriate behavior by employees that occurred years ago, when he was at GSK. The British drugmaker said an investigation into Slaoui’s behavior had corroborated the allegations.

Regardless of his decisions, GSK’s damn accusation on Wednesday leaves little room for Slaoui’s career in today’s biopharmaceutical industry. Centessa Pharmaceuticals ’newly launched megabiotechnology immediately broke up with him, just a month after choosing him as chief scientific officer.

RELATED: GSK sever ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename the R&D site

Centessa’s management and board “were concerned to learn of yesterday’s news regarding Dr. Slaoui,” Centessa CEO Saurabh Saha, MD, said in a statement Thursday. “Centessa is absolutely committed to nurturing a culture of respect that is free from any harassment and discrimination.”

Centessa has established a large venture capital venture for medicine science Medicxi, of which Slaoui has been a partner since September 2017. As of Thursday morning, an introduction to Salou can still be seen on the Medicxi website, and the company did not immediately respond to a request for comment. Through a European investment store, Slaoui also holds positions on the boards of other Medicxi companies in the portfolio, such as the British biotech company Divide & Conquer.

RELATED: Warp Speed ​​boss Slaoui resigns at Biden’s request because COVID-19 shooting: report

U.S. vaccine developer Vaxcyte said Thursday that Slaoui has resigned as president. Medixci also participated in the company’s previous round of financing when the firm was known as SutroVax.